October 26, 2016 5:53 AM ET


Company Overview of Hetero Drugs Limited

Company Overview

Hetero Drugs Limited, a pharmaceutical company, develops, manufactures, and markets active pharmaceutical ingredients (APIs), intermediate chemicals, and generic finished dosages in India. The company offers APIs in the areas of antiretroviral and oncology products to the global pharmaceutical market; finished dosages in various therapeutic areas, including antiretroviral, gastro-intestinal, cardiovascular, antidepressants/antipsychotics, anti-diabetics, pain management, anti-infectives, dermatology, and oncology; and oncology products, including injectables, solid/liquid oral dosages, ointments, soft gelatine capsules, and inhalers. It also develops and manufactures bio-generics; and provid...




Hyderabad,  500018


Founded in 1993


91 40 2370 4923


91 40 2370 4926

Key Executives for Hetero Drugs Limited

Founder, Chairman and Managing Director
Age: 62
Whole Time Director
Age: 59
Director of Production and Whole Time Director
Age: 47
Compensation as of Fiscal Year 2016.

Hetero Drugs Limited Key Developments

Hetero Bags DCG(I) Approval for Generic Version of Daclatasvir Tablets

Hetero has received the approval from Drug Controller General (India) for the generic version of Daclatasvir tablets (30mg, 60mg). The product in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infections, which is highly prevalent in India. The product is a generic version of Bristol-Myers Squibb's brand 'Daklinza,' approved by US FDA in July 2015. Daclatasvir is one of the direct-acting antivirals for hepatitis C treatment. Research studies indicates that this drug enables the rapid decline of Hepatitis C virus. Daclatasvir is included the World Health Organization's List of Essential medicines.

Cipla Reportedly Mulls Acquisition Of Hetero’s US Business

Cipla Limited (NSEI:CIPLA) is in talks to acquire US business of Hetero Drugs Limited, which is run under the Camber Pharmaceuticals brand, according to sources. The deal, which may be announced in the next few days, values Hetero's US business at $500-550 million and may including manufacturing facilities, sources added. When contacted by CNBC-TV18, Cipla said that it did not want to comment on any product or partner discussions and that it was "constantly in discussions with multiple partners on potential collaborations". "Our aspiration is to drive access to and ensure availability of affordable medicines," Cipla said.

Hetero Announces the Launch of Biosimilar Rituximab MABALL in India

Hetero Group announced the successful launch of its biosimilar 'Rituximab' under the brand name MABALL in India. The launch of biosimilar Rituximab will provide a much needed access to patients in India suffering with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL). Rituximab is recommended as the first-line treatment for NHL and is available in a single dose vial with two strengths - 100mg/10ml and 500mg/50ml.

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Hetero Drugs Limited, please visit www.heterodrugs.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.